Mipomersen and its use in familial hypercholesterolemia

References

• Hopkins P, Toth P, Ballantyne CM, et al. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the national lipid association expert panel on familial hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3 Suppl):S9–17.
   PubMed Web of Science ®Google Scholar
• Reiner Z. Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol. 2015;12:565–575.
   PubMed Web of Science ®Google Scholar
• Abifadel M, Elbitar S, El Khoury P, et al. Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. Curr Atheroscler Rep. 2014 Sep;16(9):439.
   PubMed Web of Science ®Google Scholar
• Cuchel M, Bruckert E, Ginsberg H. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. Eur Heart J. 2014;35(32):2146–2157.
   PubMed Web of Science ®Google Scholar
• Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013 Apr 13;381(9874):1293–1301.
   PubMed Web of Science ®Google Scholar
• Sjouke B, Kusters D, Kindt I, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome. Eur Heart J. 2014 Feb 28. DOI:10.1093/eurheartj/ehu058
   PubMed Web of Science ®Google Scholar
• More Detailed information on Key Tier 1 applications – Familial Hypercholesterolemia. Center for surveillance, epidemiology and laboratory services (CSELS), public health genomics. Atlanta (GA): CDC; 2014. Available from: https://www.cdc.gov/genomics/implementation/toolkit/fh_1.htm
   Google Scholar
• Reiner Z. Treatment of children with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2018;25(10):1095–1097.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124:2202–2207.
   Google Scholar
• Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolemia from the international FH foundation. J Clin Lipidol. 2014;8:148–172.
   PubMed Web of Science ®Google Scholar
• Nordestgaard B, Chapman M, Humphries S. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–90a.
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events. J Am Coll Cardiol. 2014;64:485–494.1.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:341–350.
   PubMed Web of Science ®Google Scholar
• Nikolic D, Mikhailidis DP, Davidson MH, et al. ETC1002: a future option for lipid disorders? Atherosclerosis. 2015;237:705–710.
   Web of Science ®Google Scholar
• Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259–293.
   PubMed Web of Science ®Google Scholar
• Davis RA. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim Biophys Acta. 1999;1440:1–31.
   PubMed Web of Science ®Google Scholar
• Genyzme Corporation. KYNAMRO® (mipomersen sodium) injection prescribing information. 2013. [cited 2018 Jun 5]. Available from: http://www.kynamro.com/~/media/Kynamro/Files/KYNAMRO-PI.pdf
   Google Scholar
• Yu RZ, Lemonidis KM, Graham MJ, et al. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol. 2009;77:910–919.
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006;114:1729–1735.
   PubMed Web of Science ®Google Scholar
• Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J. 2011;32:2650–2659.
   PubMed Web of Science ®Google Scholar
• Akdim F, Stroes ES, Sijbrands EJ, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol. 2010;55:1611–1618.
   PubMed Web of Science ®Google Scholar
• Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105:1413–1419.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.
   PubMed Web of Science ®Google Scholar
• McGowan MP, Tardif JC, Ceska R, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012;7:e49006.
   PubMed Web of Science ®Google Scholar
• Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126:2283–2292.
   PubMed Web of Science ®Google Scholar
• Thomas GS, Cromwell WC, Ali S, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013;62:2178–2184.
   PubMed Web of Science ®Google Scholar
• Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J. 2015 Mar 1;36(9):566–575.
   PubMed Web of Science ®Google Scholar
• Duell PB, Santos RD, Kirwan BA, et al. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. J Clin Lipidol. 2016 Jul-Aug;10(4):1011–1021.
   PubMed Web of Science ®Google Scholar
• Waldmann E, Vogt A, Crispin A, et al. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (the MICA study). Atherosclerosis. 2017;259:20–25.
   PubMed Web of Science ®Google Scholar
• Li N, Li Q, Tian XQ, et al. Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. 2014;5:367–376.
   PubMed Web of Science ®Google Scholar
• Yu RZ, Kim TW, Hong A, et al. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos. 2007;35(3):460–468.
   PubMed Web of Science ®Google Scholar
• Yu RZ, Geary RS, Flaim JD, et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2′-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet. 2009;48:39–50.
   PubMed Web of Science ®Google Scholar
• Li Z, Hard ML, Grundy JS, et al. Lack of clinical pharmacodynamic and pharmacokinetic drug-drug interactions between warfarin and the antisense oligonucleotide mipomersen. J Cardiovasc Pharmacol. 2014;64:164–171.
   PubMed Web of Science ®Google Scholar
• Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129:1022–1032.
   PubMed Web of Science ®Google Scholar
• Hashemi N, Odze RD, McGowan MP, et al. Liver histology during mipomersen therapy for severe hypercholesterolemia. J Clin Lipidol. 2014 Nov-Dec;8(6):606–611.
   PubMed Web of Science ®Google Scholar
• Husten L. Europe and US diverge on two new drugs. Forbes. 2013 Mar. [cited 2018 Oct 13]. Available from: https://www.forbes.com/sites/larryhusten/2013/03/22/europe-and-us-diverge-on-two-new-drugs/#30f97169246
   Google Scholar